Minoxidil-Finasteride Liniment and Foam for Faster Alopecia Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alopecia, particularly androgenic alopecia, suffer from slow onset, unsatisfactory effects, and significant side effects, necessitating the development of a pharmaceutical composition that addresses these issues.
Innovation Solution
A pharmaceutical composition comprising 5% minoxidil and 0.075% finasteride, formulated as a foam or liniment, which is designed to provide rapid and effective hair growth promotion with minimal side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional pharmaceutical compositions for alopecia treatment are used, then treatment coverage is provided, but the onset is slow and therapeutic effects are unsatisfactory
Solution Approach 1:
The patent combines minoxidil and finasteride into a single pharmaceutical composition, merging the hair growth promotion effects of minoxidil with the hair loss prevention effects of finasteride. This combination allows both mechanisms to work synergistically, accelerating the therapeutic onset and improving overall efficacy compared to single-agent treatments.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing both minoxidil and finasteride in specific concentrations. This composite composition leverages the complementary pharmacological properties of both active ingredients, producing a faster and more satisfactory therapeutic effect than either component alone.
2Reliability
If conventional pharmaceutical compositions for alopecia treatment are used, then treatment is provided, but side effects are significant
Solution Approach 1:
The patent optimizes the concentration parameters of both minoxidil and finasteride in the composition, along with adjusting formulation parameters such as vehicle composition and pH. These parameter changes enable the formulation to achieve effective treatment while minimizing side effects through improved drug delivery and reduced local irritation.
3Ease of operation
If foam formulation is used, then ease of application and reduced irritation are achieved, but formulation complexity increases
Solution Approach 1:
The patent utilizes the foam phase transition state, where the pharmaceutical composition is transformed into a foam formulation that can be easily applied to the scalp. This phase transition provides benefits including improved spreadability, reduced irritation, and better patient compliance, while the foam structure itself simplifies the application process despite the increased formulation complexity.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides a pharmaceutical formulation for treating alopecia, a preparation method therefor and the use thereof. Specifically, the present invention provides a formulation or composition for treating alopecia, comprising the following active components on the basis of the mass percentage (w/w) or mass/volume percentage (w/v): (a) 5% of minoxidil; and (b) 0.07-0.095% of finasteride; the formulation or the composition is a foaming agent or a liniment; and when the formulation is a foaming agent, the total mass in the mass percentage does not contain the mass of a propellant. The foaming agent and liniment of the present invention take effect quickly and have good effects and few side effects.